This study was designed to assess the effects of dietary supplementation with n-3 polyunsaturated fatty acids (PUFA) from fish oil on the response of doxorubicininduced chronic heart failure in rats. Male Sprague-Dawley rats were treated daily for 8 weeks with normal saline or n-3 PUFA intragastrically after induction of myocardial injury by intraperitoneal injection of doxorubicin 2 mg/kg once weekly for 8 weeks. Cardiac function was assessed by echocardiography. The cytoprotective role of n-3 PUFA against doxorubicin-induced myocardial injury was demonstrated by light microscopy, and serum cytokines (tumour necrosis factor-a and interleukin-10) were analysed by enzyme-linked immunosorbent assay. Doxorubicin induced death, alterations in echocardiography parameters and histological damage, all of which are features that characterize heart failure. There were significant differences between the doxorubicin-induced heart failure group and the n-3 PUFA-treated group in terms of echocardiography parameters and cytokine changes. Thus, dietary supplementation with n-3 PUFA attenuated doxorubicin-induced cardiac dysfunction, an effect that might be associated with recovery from an imbalance of the cytokine network.
Introduction
Heart failure is a complex clinical syndrome with a number of causes. Despite aggressive treatment, heart failure leads to substantial morbidity and mortality, and is on the increase in most regions of the world. 1 Prevention of heart failure is an important clinical and public health priority, 2, 3 particularly since an ageing population is expected to increase the incidence and prevalence of heart failure. 3 Thus, there is a need for novel adjunctive therapies that act in ways unlike those of the current established therapies.
Evidence from clinical trials and cohort studies has indicated that a diet rich in n-3 polyunsaturated fatty acids (PUFA) reduces the plasma level of triglycerides, 4 the *These authors contributed equally to this work. LL Teng, L Shao, YT Zhao et al. Effect of n-3 PUFA in a chronic heart failure model frequencies of cardiac arrhythmias and sudden death, 5 and the risk of ischaemic heart disease 6 and is, therefore, recommended for optimal cardiovascular health. 7 The most common source of n-3 PUFA is fish oil, which is high in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Epidemiological and experimental studies have suggested that n-3 PUFA of marine origin may prevent the development and progression of heart failure. 8, 9 The mechanism of the potential beneficial effect of fish oil in the prevention of heart failure is, however, unclear. It may prevent the development and progression of heart failure by favourably affecting inflammation, the plasma lipid profile, 10,11 blood pressure 12 and cardiac mitochondrial function. 13, 14 It has been reported previously that n-3 PUFA affects circulating inflammatory markers and N-terminal probrain natriuretic peptide (NT-proBNP) in patients with chronic heart failure. 15 In the present study, the effects of dietary n-3 PUFA from fish oil on cardiac function and histological changes were examined in a rat model of chronic heart failure induced by doxorubicin. It was hypothesized that improvement of cardiac function by n-3 PUFA supplementation might be related to restoration of the balance of the cytokine network.
Materials and methods

CHEMICALS
Doxorubicin was obtained from Zhejiang Haizheng Pharmaceutical Co. Ltd, Taizhou City, Zhejiang Province, China. The n-3 PUFA, which is derived from fish (menhaden) oil (21% EPA and 49% DHA by weight), was obtained from Sigma-Aldrich, St Louis, MO, USA. All other chemicals used were of analytical grade.
ANIMAL CARE
Adult male Sprague-Dawley rats (mean ± SD weight 250 ± 10 g) were obtained from Fudan University, Shanghai, China (certificate No. SYXK 2007-0002) and all protocols described were approved by the Animal Ethics Committee of Fudan University. All rats were acclimatized to animal house conditions for 2 weeks, fed commercial pelleted rat chow (Shanghai Laboratory Animal Centre of the Chinese Academy of Sciences, Shanghai, China) and had free access to water.
EXPERIMENTAL DESIGN AND ECHOCARDIOGRAPHY
The rats were initially divided into a control group (10 rats) and a doxorubicin group (36 rats) . Rats in the doxorubicin group were injected intraperitoneally with doxorubicin (2 mg/kg once weekly for 8 weeks) to induce myocardial injury; rats in the control group received an equivalent volume of 0.9% normal saline according to the same schedule. After the heart failure model had been established at the end of the 8-week period of doxorubicin treatment, cardiac function was measured by echo cardiography using a high-resolution in vivo microimaging system for small animals (Vevo 770 ® ; VisualSonics, Toronto, ON, Canada) with a 10 MHz imaging transducer. Briefly, each animal was slightly sedated with an intraperitoneal injection of 20 mg/kg sodium pentobarbital. M-mode images of the left ventricle at the midcord level were recorded, and left ventricular end-diastolic dimension (LVEDD) and left ventricular end-systolic dimension (LVESD) were measured by the leading edge method. The mean from three cardiac cycles was used to calculate fractional shortening (FS) as follows: FS (%) = ([end-diastolic dimension − endsystolic dimension]/end-diastolic dimension) × 100. LL Teng, L Shao, YT Zhao et al. Effect of n-3 PUFA in a chronic heart failure model A total of 10 rats from the original doxorubicin group died and were excluded from any further analysis. The surviving rats that had been treated with doxorubicin were then divided randomly into two groups: the n-3 PUFA group (13 rats) and the heart failure group (13 rats). Rats in the n-3 PUFA group were treated intragastrically using a stomach tube with fish oil (0.6% of body weight) daily for 8 weeks; rats in the heart failure and control groups received an equivalent volume of normal saline daily for 8 weeks.
Echocardiography was again performed, as described above, at the end of the 8-weeks.
BLOOD SAMPLING AND CYTOKINE ANALYSIS
Survival analysis was performed in all groups. During the study period, cages were inspected daily for animals that had died. At the end of the intervention period, each animal was anaesthetized with diethyl ether and then killed. Blood samples were obtained directly from the heart. The heart was rapidly excised and washed thoroughly with cold saline. After the atria had been removed, the ventricles were snap-frozen in liquid nitrogen. Samples used for lipid analysis were lyophilized before measurement. Whole blood that had been collected into vacuum blood collection tubes (pro-coagulation tubes) was centrifuged and serum was stored at −80°C prior to measurement of tumour necrosis factor-α (TNF-α) and interleukin-10 (IL-10) levels. These were measured by enzyme-linked immunosorbent assay using a TNF-α assay kit and a IL-10 assay kit (both from R & D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
HISTOLOGICAL ANALYSIS
Cardiac tissue was examined by light microscopy. Tissues were snap-frozen in liquid nitrogen and 5-µm frozen sections were prepared and stained with haematoxylin and eosin for histological examination. Three fields randomly chosen from the septal, posterior and left ventricular wall were examined.
STATISTICAL ANALYSIS
Statistical analysis was performed using the SPSS ® statistical package, version 14.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Continuous variables were expressed as mean ± SD. Differences in mean values between groups were analysed using the Student's t-test for normally distributed variables and the Mann-Whitney U-test for non-normally distributed variables. The paired t-test and Wilcoxon paired test were used to compare means before and after therapy with n-3 PUFA or saline. A value of P < 0.05 was considered to be statistically significant.
Results
During the second week after beginning doxorubicin administration, the development of enlarged abdomens associated with ascites was observed in several animals. This led to poor clinical status and these animals, three rats in the heart failure group and one rat in the n-3 PUFA group, were killed before the end of the study period and not included in the analysis. Thus, 32 rats were included in the final analysis, 10 in the control group, 10 in the heart failure group and 12 in the n-3 PUFA group.
Representative echocardiography maps and the parameters of cardiac function of the control, heart failure and n-3 PUFA groups are shown in Fig. 1 and Table 1 , respectively. Compared with rats in the heart failure group, rats in the n-3 PUFA group had significantly lower LVEDD and LVESD, and LL Teng, L Shao, YT Zhao et al. Effect of n-3 PUFA in a chronic heart failure model significantly higher LVEF and LVFS at the end of the n-3 PUFA/saline treatment period (P < 0.05 for all comparisons). At the same time, rats in the heart failure and n-3 PUFA groups had significantly higher LVEDD and LVESD and significantly lower LVEF and LVFS than rats in the control group (P < 0.05 for all comparisons).
Serum TNF-α and IL-10 levels in the control, heart failure and n-3 PUFA groups are shown in Table 2 . Compared with control group rats, those in the heart failure and n-3 PUFA groups had significantly higher levels of TNF-α and IL-10 (P < 0.05 for all comparisons). Rats in the heart failure group also had significantly higher levels of TNF-α and IL-10 compared with those in the n-3 PUFA group (P < 0.05 for all comparisons).
Normal morphological findings were seen in the control group ( Fig. 2A) . In contrast, morphological changes were found in the heart failure group; heart tissue in this group showed severe swelling of mitochondria and nuclei, focal subendocardial fibrosis, and disorganization (Fig. 2B) . Rats in the n-3 PUFA group also showed changes in heart tissue, but these were less severe than in the heart failure group (Fig. 2C ).
FIGURE 1:
Representative echocardiography maps of the three groups of rats: (A) control group, no doxorubicin treatment for 8 weeks, then saline only for a further 8 weeks (n = 10); (B) heart failure group, 2 mg/kg doxorubicin weekly for 8 weeks then saline for a further 8 weeks (n = 10); (C) n-3 polyunsaturated fatty acid (PUFA) group, 2 mg/kg doxorubicin weekly for 8 weeks, then n-3 PUFA (fish oil at 0.6% of body weight daily) for a further 8 weeks (n = 12) 
Discussion
Cancer chemotherapy with anthracyclines has been hampered by the dose-dependent risk of cardiomyopathy and the potential appearance of irreversible fatal congestive heart failure. The primary objective of the present study was to examine the ability of n-3 PUFA to affect doxorubicin-induced heart failure in rats, using both functional (echocardiography) and histological endpoints. In the rat, anthracycline cardiotoxicity has been shown to depend on the dose, route of administration and schedule of administration. Toxicological studies have demonstrated that doxorubicin induces severe cardiotoxicity at 9 mg/kg when administered intravenously 16 and at 16 mg/kg when administered intraperitonally. 17 To evaluate the effect of n-3 PUFA on doxorubicin-induced heart failure, a cumulative intraperitoneal dose of 16 mg/kg doxorubicin (2 mg/kg once weekly for 8 weeks) was selected as being appropriate for the detection of an increased risk of cardiomyopathy. As expected, significant increases in LVEDD and LVESD, and marked FIGURE 2: Haematoxylin-eosin-stained sections of myocardium: (A) the control group, no doxorubicin treatment for 8 weeks, then saline only for a further 8 weeks (n = 10), showed normal morphological findings; (B) the heart failure group, 2 mg/kg doxorubicin weekly for 8 weeks then saline for a further 8 weeks (n = 10) showed severe swelling of mitochondria and nuclei, focal subendocardial fibrosis, and disorganization; (C) n-3 polyunsaturated fatty acid (PUFA) group, 2 mg/kg doxorubicin weekly for 8 weeks, then PUFA (fish oil at 0.6% of body weight daily) for a further 8 weeks (n = 12) showed similar, though less pronounced changes to those seen in the heart failure group Serum concentrations of tumour necrosis factor-a (TNF-a) and interleukin 10 (IL-10) in untreated control rats and in doxorubicin-treated heart failure model rats receiving fish oil at 0.6% of body weight daily (n-3 PUFA group) or saline (heart failure group) for 8 weeks LL Teng, L Shao, YT Zhao et al. Effect of n-3 PUFA in a chronic heart failure model decreases in LVEF and LVFS were observed with the administration of doxorubicin, together with the enlarged abdomen associated with ascites in several animals. All of these criteria validated the rat model.
Several studies have already stressed a beneficial effect of n-3 PUFA on anthracycline-induced cardiotoxicity in vivo, although this has not been demonstrated in all studies. 18 Schjott et al. 19 reported that EPA and, to a lesser extent, DHA decreased anthracycline-induced toxicity. More recently, it was found that an oil containing γ-linolenic acid had cardioprotective properties against doxorubicin-induced cardiotoxicity similar to those of dexrazoxane but with less general toxicity in a rat model. 20 Some hypotheses have been proposed to explain the mechanism responsible for the beneficial effect of these agents: it could be mediated by the replacement of anthracycline-peroxidized fatty acids in lipid-containing structures such as membranes, 20, 21 or by alterations in eicosanoid metabolic pathways. 18, 19 In the present study, it was observed that cardiac function and histological changes greatly improved after treatment with n-3 PUFA. Thus, we speculate that n-3 PUFA attenuates doxorubicin-induced cardiac dysfunction, an effect that might be associated with restoration of an imbalance of the cytokine network.
Because heart failure is associated with increased levels of inflammatory mediators, such as eicosanoids 22 -24 and cytokines, 25 -29 there is now considerable interest in the relationship between n-3 PUFA and heart failure. A significant reduction in the TNF-α level was observed after treatment with n-3 PUFA in the present study, which is consistent with a previous report. 15 Cytokines are intercellular signalling molecules that mediate and regulate immune and inflammatory responses, stimulate haematopoietic function, and are involved in tissue repair and other physiological and pathological processes. In normal, non-stress conditions, the myocardium does not express inflammatory cytokines, but myocardial and plasma cytokine levels are increased during heart failure. 30 Many cytokines, such as TNFα and IL-6, are related to cardiac suppression and heart failure, and their excessive release leads to left ventricular dysfunction, pulmonary oedema, ventricular remodelling, apoptosis and endothelial cell dysfunction. 31 An animal study found that TNF-α reduced LVEF and that removal of the effect of TNF-α fully restored cardiac contractility. 32 The present study showed that the serum TNF-α level in the heart failure group was significantly higher than in the control group.
By inhibiting the activation of monocytes and macrophages, IL-10 inhibits macrophages and vascular smooth muscle cells expressing TNF-α, IL-6 and other cytokines, and affects the occurrence and development of a variety of cardiovascular diseases. 33 As an anti-inflammatory cytokine, IL-10 can counteract the effects of inflammatory cytokines generated in the process of congestive heart failure and its action may be directed against the myocardial damage mediated by inflammatory cytokines. In the present study, the serum IL-10 level in the heart failure group was significantly higher than that in the control group, suggesting that IL-10 has an important role in the heart failure development process. After treatment with fish oil for 8 weeks in rats with doxorubicininduced heart failure, serum levels of the TNF-α inflammatory cytokine and of the IL-10 anti-inflammatory cytokine were significantly lower than those in the heart failure group. The IL-10/TNF-α ratio in the n- 3 PUFA group was also lower than that in the heart failure group. This ratio reflects the balance of pro-and anti-inflammatory states; the closer the balance is to a state of equilibrium, the more conducive it is to the resumption of inflammatory diseases. Thus, we speculate that n-3 PUFA improves cardiac function by regulating the balance of the cytokines TNF-α and IL-10.
The mechanism of the effect of n-3 PUFA on TNF-α and IL-10 may be linked to its ability to modulate transcription factors. Cytokine synthesis is regulated by nuclear transcription factor-κB (NF-κB), 34 which is activated in heart failure. 35, 36 In vitro, EPA has been shown to prevent lipopolysaccharide-induced NF-κB activation and the expression of TNF-α mRNA. 37 The activity of NF-κB is negatively regulated by peroxisome proliferator-activated receptors (PPARs) in neonatal rat cardiac myocytes, where PPAR-α and -γ agonists inhibit NF-κB activation and expression of TNF-α mRNA in response to lipopolysaccharide. 38 Thus, n-3 PUFA activation of PPARs may lead to the suppression of NF-κB and NF-κB-regulated pro-inflammatory cytokines. It could be speculated that the favourable effect of n-3 PUFA on doxorubicin-induced heart failure may be ascribed to restoration of the balance of pro-and anti-inflammatory factors.
In conclusion, the present investigation has extended earlier reports regarding the protective action of n-3 PUFA against heart failure by demonstrating that this protective effect might be due to the ability of n-3 PUFA to reverse an imbalance of the cytokine network. Further studies are in progress to elucidate the exact mechanisms of action of n-3 PUFA and its potential in the treatment and/or prevention of heart failure.
